Skip to main content
Clinical Trials/IRCT20160221026674N5
IRCT20160221026674N5
Not Yet Recruiting
Phase 3

Investigating the added value of sensory retraining to duloxetine on pain, sensory symptoms, nerve conduction velocity, hand dexterity and static balance in patients with chemotherapy-induced sensory peripheral neuropathy- a controlled clinical trial study

Shiraz University of Medical Sciences0 sites34 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Shiraz University of Medical Sciences
Enrollment
34
Status
Not Yet Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age over 40 years
  • Reporting the presence of symptoms of peripheral neuropathy including pain, numbness, tingling and any abnormal sensations by the patient
  • A score of at least 4 out of 10 in at least one of the symptoms of neuropathy in the numeric rating scale of pain in the hands and feet in the last week
  • Completion of the chemotherapy course of patients at least 3 months and at most 9 months before the start of the study and the existence of life expectancy for at least 6 months

Exclusion Criteria

  • The presence of other types of peripheral neuropathy before the start of chemotherapy
  • The presence of any wound or swelling in the treatment area (hands and feet)
  • Epilepsy or cardiac arrhythmia or the presence of a pacemaker in the patient's heart
  • Suffering from diabetes, hyperthyroidism, kidney failure, hepatitis, AIDS and vitamin B12 deficiency
  • Use of drugs such as Gabapentin and Pregabalin by patients during the study period

Outcomes

Primary Outcomes

Not specified

Similar Trials